Veeva (VEEV) earned another named Top 20 pharma commitment from Gilead Sciences (GILD), marking another proof point for Vault CRM, Raymond James tells investors in a research note. The firm, which has an Outperform rating on Veeva shares, says that it is increasingly resonating that Veeva has cultivated a right to win as a partner of choice in CRM as Salesforce (CRM) works to get a product live in market later this year.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- Veeva says Gilead commits to Veeva Vault CRM
- Alphabet downgraded, Boeing upgraded: Wall Street’s top analyst calls
- Veeva upgraded to Overweight from Neutral at JPMorgan
- Veeva Systems: Strong Growth Potential and Strategic Positioning in the Life Sciences Industry
- Veeva Systems’ Earnings Call Highlights Strategic Wins